Adding Pioglitazone to Imatinib May Improve Treatment of Chronic Myeloid Leukemia
the ONA take:
Patients with chronic myeloid leukemia (CML) who received imatinib plus pioglitazone, a drug commonly used to treat type 2 diabetes, achieved a sustained complete molecular response for up to 4.7 years after the withdrawal of the antidiabetes medication, a recent study published online in the journal Nature has shown.
For the study, Philippe Leboulch, MD, PhD, from Brigham & Women’s Hospital and Harvard Medical School Genetics Division in Boston, Massachusetts, and colleagues temporarily treated three patients with CML in chronic residual disease despite continuous treatment with imatinib with pioglitazone. When pioglitazone activates PPARγ, the expression of STAT5, HIF2α and CITED2 is decreased. These downstream signaling targets play a role in the CML leukemia stem cells that tyrosine kinase inhibitors such as imatinib may fail to eradicate.
"When pioglitazone was given temporarily to three chronic myeloid leukemia patients in chronic residual disease in spite of continuous treatment with imatinib, all of them achieved sustained complete molecular response, up to 4.7 years after withdrawal of pioglitazone," the authors write.
"This suggests that clinically relevant cancer eradication may become a generally attainable goal by combination therapy that erodes the cancer stem cell pool."
Imatinib is already approved by the US Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase, as well as those in blast phase, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.
Erosion of the chronic myeloid leukaemia stem cell pool by PPAR[ggr] agonists : Nature : Nature Publ
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|